BCAB
BioAtla, Inc.
Healthcare · Biotechnology · NCM
$3.33
Data: 2026-05-13
✗ ETHICAL FAIL

MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$8M
Total market value of the company
Trailing P/E
0.00
Forward P/E
-3.53
Based on estimated future earnings — lower means cheaper
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
ROE
0.0%
Return on equity — how efficiently it uses shareholder money
Analyst Target
N/A
Recommendation
NONE
Consensus view from ? analysts covering this stock
About BioAtla, Inc.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

https://www.bioatla.com

Country: United States Employees: 41 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
79.1% FAIL
Debt must be below 33% of total assets
Cash Ratio
90.9% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKDOWN
Price trending down — defensive positioning
Sharpe Ratio
-0.639
Returns do not compensate for the risk — negative edge
Kelly Fraction
-0.0768
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.812
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-78.7%
Historical annualised return based on price data
Max Drawdown
-97.0%
Largest peak-to-trough decline — the worst it has been
HMM State
BULL
Statistical model sees bullish momentum
Days in State
14
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
0.79
Less volatile than the market — more defensive
52W High
$71.50
95% below the year high
52W Low
$3.92
-15% above the year low
Avg Volume
38,975
Average daily shares traded — higher means easier to buy and sell
Short Ratio
2.9
Days it would take all short sellers to cover — higher means more crowded
Short % Float
8.9%
Moderate short interest
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-50.50
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.00
Conservative use of debt — low financial risk
Current Ratio
0.37
Below 1 means short-term obligations exceed liquid assets — risk flag
Quick Ratio
0.33
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
-462.8%
Profit from core operations before interest and tax
Free Cash Flow
$-22,801,624
Negative — the business is spending more than it generates
Revenue (TTM)
$2M
Total revenue over the last 12 months
Net Income
$-59,607,000
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-03-11 SHORT JAY M Chief Executive Officer 430,000 —
2026-03-10 VASQUEZ CHRISTIAN J Chief Financial Officer 240,000 —
2026-03-10 SIEVERS ERIC L Officer 240,000 —
2025-06-18 STEINMAN LAWRENCE Director 23,500 —
2025-06-18 MORAN SUSAN Director 23,500 —
2025-06-18 GRAY MARY ANN Director 23,500 —
2025-06-18 MCBRINN SYLVIA Director 23,500 —
2025-06-18 SMITH SCOTT ANDREW Director 23,500 —
2025-06-18 WILLIAMS EDDIE Director 23,500 —
2025-03-12 SHORT JAY M Chief Executive Officer 431,000 —
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.